Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroFuse-033: sacituzumab tirumotecan + pembrolizumab vs pembrolizumab for pMMR endometrial carcinoma maintenance
ChiCTR2500107437Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and sacituzumab tirumotecan in endometrial cancer (EC) (4 arms), sponsored by Peking University People's Hospital. Primary endpoints: Progression-Free Survival (PFS) and Overall Survival (OS). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
pembrolizumabsacituzumab tirumotecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2500107437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107437.